Current financial headlines

Sharemaestro Newsreel

Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.

Showing: 1–36
Headlines: 212
Sources here: 2
Companies here: 11

Current section Mexico Drug Manufacturers - General news Latest headline 07:15, 14 August 2026

Latest07:15 · 14 August 2026

finance.yahoo.com Capital return

Bekaert: Update on the Share Buyback Program and the Liquidity Agreement

Bekaert Update on the Share Buyback Program and the Liquidity Agreement Period from 6 August 2026 to 12 August 2026 Share Buyback Program On 26 February 2026, Bekaert announced the start of the next tranche of its share buyback program, for a total maximum consideration of up to € 75 million. As announced previously, the purpose of the …

Provider-linked mention 🇲🇽 Mexico

Read at finance.yahoo.com

Sharemaestro market context Price above Trend Line 52 weeks +47.4% · Next-week setup negative 19.6%

Just inNext headlines

07:00 14 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇲🇽 Mexico

AFARAK GROUP: INTERIM REPORT H1 2026

Afarak Group SE 07:00 London, 09:00 Helsinki, 14 August 2026 - Afarak Group SE ("Afarak" or "the Company") (LSE: AFRK, NASDAQ: AFAGR) FINANCIAL INTERIM RELEASE H1 2026 H1/26 H1/25 2025 Revenue EUR million 57.1 77.1 141.3 EBITDA EUR million 1.6 6.9 -0.2 EBIT EUR …

BAYNN mentioned

Sharemaestro market context Price above Trend Line 52 weeks +47.4% · Next-week setup negative 19.6%

00:38 14 Aug 2026

finance.yahoo.com Regulatory and legal Main company 🇲🇽 Mexico

Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?

On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator's choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +8.3%

Chronological news

Latest headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

00:09 14 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇲🇽 Mexico

MLP SE (WBO:MLP) (Q2 2026) Earnings Call Highlights: Record Revenue and EBIT Fuel Optimistic Outlook

This article first appeared on GuruFocus. Total Revenue: Increased by 10% to a record EUR583 million in the first half of 2026. EBIT: Reached a new record high of EUR64 million in the first half of 2026. Revenue by Competence Field: Property & Casualty …

BAYNN mentioned

Sharemaestro market context Price above Trend Line 52 weeks +47.4% · Next-week setup negative 19.6%

00:07 14 Aug 2026

finance.yahoo.com Market update Main company 🇲🇽 Mexico

Johnson & Johnson (JNJ)’s $5.5B Talc Settlement: Turning Point or Temporary Relief?

The World Health Organization projects that the share of the world's population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +32.5%

22:46 13 Aug 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)’s Partnership Create the Next Big Pharma Growth Engine

Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn't always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this …

GILD main company

Sharemaestro market context Price below Trend Line 52 weeks +4.3%

22:33 13 Aug 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?

AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which exceeded internal expectations …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +8.3%

22:12 13 Aug 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

Product Image (Photo: Bristol Myers Squibb)ZENBEXUS™ (iberdomide) Logo Approval based on EXCALIBER-RRMM results showing ZDd doubled minimal residual disease-negative complete response rates versus daratumumab, bortezomib and dexamethasone (41% vs. 21%) in relapsed or refractory multiple myeloma(1) ZENBEXUS marks the arrival of a new treatment …

BMY main company

Sharemaestro market context Trend signal started 52 weeks +23.9%

21:07 13 Aug 2026

finance.yahoo.com Analyst action Main company 🇲🇽 Mexico

Merck (MRK) Stock Fair Value Edges Higher After Analysts Back Pipeline Progress

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Price target commentary for Merck has shifted toward a US$140 to US$155 range, anchored by a modest uplift in fair value from US$132.78 to …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +39.2% · Next-week setup negative 43.6%

19:38 13 Aug 2026

finance.yahoo.com Market update Main company 🇲🇽 Mexico

Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish obesity-drug giant behind Wegovy and Ozempic, slipped approximately 1% Thursday morning as CEO Mike Doustdar tried to reset the market's thinking about the obesity race. His pitch: stop treating Novo versus Eli Lilly …

NOVOBN main company NVON main company

Sharemaestro market context Price above Trend Line 52 weeks -15.6%

18:20 13 Aug 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?

Novo Nordisk (NYSE: NVO) posted strong first-quarter results and performed fairly well in the month that followed its first-quarter update. However, the company's most recent financial update, for the second quarter, erased much of those gains. In both cases, the market's reaction was largely …

NOVOBN main company NVON main company

Sharemaestro market context Price above Trend Line 52 weeks -15.6%

16:12 13 Aug 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

Novo Nordisk (CPSE:NOVO B) Sees New Pressure In Weight Loss Drugs

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk (CPSE:NOVO B) faces fresh competition as the UK's MHRA approves Eli Lilly's oral weight loss therapy Foundayo for use in the …

NOVOBN main company NVON main company

Sharemaestro market context Price above Trend Line 52 weeks -15.6%

14:52 13 Aug 2026

finance.yahoo.com Analyst action Main company 🇲🇽 Mexico

Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation

Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts. For Biogen, Wolfe raised its rating from Peer Perform and set a $300 price target, arguing that the …

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +53.6% · Next-week setup negative 26.4%

13:00 13 Aug 2026

finance.yahoo.com Deals and strategy Provider-linked mention 🇲🇽 Mexico

MeiraGTx Reports Second Quarter 2026 Financial and Operational Results

MeiraGTx Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia Completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) …

JNJ mentioned

Sharemaestro market context Trend signal active 52 weeks +32.5%

10:11 13 Aug 2026

finance.yahoo.com Capital return Main company 🇲🇽 Mexico

Why Gilead Sciences (GILD) Is Back In The Spotlight

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Gilead Sciences (GILD) is back in focus after announcing a collaboration with Nucleai that applies AI powered tissue analytics to its antibody drug conjugate …

GILD main company

Sharemaestro market context Price below Trend Line 52 weeks +4.3%

03:29 13 Aug 2026

finance.yahoo.com Market update Main company 🇲🇽 Mexico

5 Insightful Analyst Questions From Pfizer’s Q2 Earnings Call

5 Insightful Analyst Questions From Pfizer's Q2 Earnings Call Pfizer's second quarter results reflected stability in its core business despite ongoing challenges in COVID-related product demand. The company's performance was shaped by strong execution in its non-COVID portfolio, with management highlighting robust revenue contributions …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks -2.9%

02:10 13 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇲🇽 Mexico

CEZ AS (XPRA:CEZ) (Q2 2026) Earnings Call Highlights: Net Income Rises 10% as Windfall Tax ...

This article first appeared on GuruFocus. Revenue: Operating revenue decreased 5% year-on-year, primarily due to lower power prices. EBITDA: Down 20% to CZK59 billion, impacted by lower generation prices and reduced trading profits. Net Income: Increased 10% to CZK18.1 billion, driven by the absence …

BAYNN mentioned

Sharemaestro market context Price above Trend Line 52 weeks +47.4% · Next-week setup negative 19.6%

02:05 13 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇲🇽 Mexico

GFT Technologies SE (WBO:GFT) (H1 2026) Earnings Call Highlights: AI-Driven Growth and ...

This article first appeared on GuruFocus. Revenue: EUR462.6 million in H1 2026, a 5% increase in both euros and constant currencies. Adjusted EBIT: EUR33 million, up 8% year-over-year, with a margin of 7.1% compared to 6.8% in H1 2025. EBT: EUR24 million, up 26% …

BAYNN mentioned

Sharemaestro market context Price above Trend Line 52 weeks +47.4% · Next-week setup negative 19.6%

00:41 13 Aug 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

5 Insightful Analyst Questions From Merck’s Q2 Earnings Call

5 Insightful Analyst Questions From Merck's Q2 Earnings Call Merck's second quarter was marked by continued sales growth, primarily driven by the strength of its oncology portfolio and contributions from new product launches. Management credited higher demand for KEYTRUDA in both early-stage and metastatic …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +39.2% · Next-week setup negative 43.6%

22:13 12 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇲🇽 Mexico

Intuitive Surgical (ISRG) Beats On Q2 As Investors Ask If The Bull Case Is Priced In

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Intuitive Surgical (ISRG) shook investors after reporting strong Q2 2026 revenue and earnings that beat expectations, while revealing slower U.S. procedure growth and …

JNJ mentioned

Sharemaestro market context Trend signal active 52 weeks +32.5%

20:58 12 Aug 2026

finance.yahoo.com Analyst action Provider-linked mention 🇲🇽 Mexico

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.2% and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

MRK mentioned

Sharemaestro market context Trend signal active 52 weeks +39.2% · Next-week setup negative 43.6%

19:36 12 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇲🇽 Mexico

Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?

Bristol Myers Squibb BMY is navigating a revenue mix shift as growth products portfolio now assumes a larger role in the business, helping mitigate the impact of declining sales from mature products facing generics. The growth portfolio — including Opdivo, Opdivo Qvantig, Orencia, Yervoy, …

MRK mentioned PFE mentioned BMY mentioned

Sharemaestro market context Trend signal active 52 weeks +39.2% · Next-week setup negative 43.6%

19:13 12 Aug 2026

finance.yahoo.com Market update Main company 🇲🇽 Mexico

Gilead Sciences (GILD) Expands ADC Research With AI Tissue Analytics

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Gilead Sciences (NasdaqGS:GILD) announced a partnership with Nucleai to use AI-powered tissue analytics in its global antibody drug conjugate programs. The collaboration focuses …

GILD main company

Sharemaestro market context Price below Trend Line 52 weeks +4.3%

18:29 12 Aug 2026

finance.yahoo.com Analyst action Main company 🇲🇽 Mexico

Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish drugmaker behind Wegovy and Ozempic, fell 2.23% intraday after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 from DKK 325 and its ADR target to $47 …

NOVOBN main company NVON main company LLY mentioned

Sharemaestro market context Price above Trend Line 52 weeks -15.6%

18:24 12 Aug 2026

finance.yahoo.com Regulatory and legal Main company 🇲🇽 Mexico

Eli Lilly Stock Falls While Retatrutide Lawsuits Expand

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the drug giant sitting at the center of the obesity boom, filed six lawsuits against businesses it says are illegally selling retatrutide. The timing is striking. Retatrutide is not approved. It is still in Phase …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +54.2%

18:20 12 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇲🇽 Mexico

Two Years Of Growth Barely Change What You Pay For Intuitive Surgical

Photo by 127071 on Pixabay Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years. Intuitive Surgical (ISRG) trades at about $401.23, roughly 32% below its 52-week high …

JNJ mentioned

Sharemaestro market context Trend signal active 52 weeks +32.5%

18:11 12 Aug 2026

finance.yahoo.com Deals and strategy Provider-linked mention 🇲🇽 Mexico

Absci (ABSI) On Early ABS 201 Data And Lilly Deal That Could Support Its Valuation

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Absci (ABSI) is back in focus after releasing early Phase 1 data for its lead antibody ABS-201 and securing a US$40 million investment and development …

LLY mentioned

Sharemaestro market context Trend signal active 52 weeks +54.2%

17:54 12 Aug 2026

finance.yahoo.com Regulatory and legal Main company 🇲🇽 Mexico

Lilly Targets Black-Market Retatrutide Sellers

This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the pharmaceutical company behind Zepbound and Foundayo, is stepping up its fight against unauthorized sellers of its experimental obesity drug retatrutide. Warning! GuruFocus has detected 8 Warning Sign with JPM. Is LLY …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +54.2%

17:12 12 Aug 2026

finance.yahoo.com Balance sheet Provider-linked mention 🇲🇽 Mexico

The Energy and Pharma Giants Quietly Funding HDV’s 3% Yield, and How Safe Each One Is

Quick Read XOM and JNJ earn 'Very Safe' dividend ratings inside HDV, backed by interest coverage of 56x and 64 consecutive annual raises. AbbVie's Skyrizi and Rinvoq are replacing Humira faster than expected, but Net Debt/EBITDA of 2.3x keeps a watchlist tag on its …

JNJ mentioned ABBV mentioned

Sharemaestro market context Trend signal active 52 weeks +32.5%

17:11 12 Aug 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

Johnson & Johnson (JNJ) Advances Seltorexant And Expands Outpatient Cardiac Care

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Johnson & Johnson (NYSE: JNJ) is advancing its novel antidepressant Seltorexant into late stage clinical development for major depressive disorder as a potential rapid …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +32.5%

16:55 12 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇲🇽 Mexico

Nextensa delivers strong half-year results, supported by several successful transactions

Nextensa NV PRESS RELEASE Regulated information Brussels, 12 August 2026, 5:55PM HIGHLIGHTS Nextensadeliversstronghalf-yearresults,supportedbyseveralsuccessful transactions Nextensa achieved strong results in the first half of 2026. The period was marked by several successful transactions, including the sale of Gewerbepark Stadlau in Vienna, the forward sale of …

BAYNN mentioned

Sharemaestro market context Price above Trend Line 52 weeks +47.4% · Next-week setup negative 19.6%

16:11 12 Aug 2026

finance.yahoo.com Market update Main company 🇲🇽 Mexico

Is Bristol Myers’ US$2.3 Billion Houston Manufacturing Campus Altering The Investment Case For BMY?

Bristol Myers Squibb recently announced it will invest about US$2.30 billion in a new 600,000-square-foot modular, multi-modal manufacturing campus at Generation Park in Houston, Texas, expected to support production of small molecules, biologics, and antibody-drug conjugates while creating nearly 500 skilled jobs and about …

BMY main company

Sharemaestro market context Trend signal started 52 weeks +23.9%

16:10 12 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇲🇽 Mexico

Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?

Novo Nordisk NVO stock has declined 4% over the past month, with the company's second-quarter 2026 results emerging as the primary factor behind the recent weakness. Although NVO beat earnings and revenue estimates, investors remained concerned about underlying growth trends in its core obesity …

LLY mentioned

Sharemaestro market context Trend signal active 52 weeks +54.2%

16:03 12 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇲🇽 Mexico

Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?

Pfizer's PFE business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products, Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral). However, the company is gradually diversifying its portfolio through a combination of internal product …

PFE main company LLY mentioned BMY mentioned

Sharemaestro market context Price above Trend Line 52 weeks -2.9%

15:46 12 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇲🇽 Mexico

TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses

Tango Therapeutics TNGX incurred a loss of 37 cents per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of 31 cents. The company had reported a loss of 35 cents per share in the year-ago quarter. …

GILD mentioned

Sharemaestro market context Price below Trend Line 52 weeks +4.3%

15:35 12 Aug 2026

nasdaq.com Analyst action Provider-linked mention 🇲🇽 Mexico

1 Vanguard ETF That Outperforms the S&P 500 and Still Has Room to Run

Key Points The "Magnificent Seven" stocks account for over 53% of this Vanguard ETF. This has helped the ETF outperform the S&P 500 in 13 of the past 20 years. Sluggish performance among its top 10 holdings has slowed returns this year.10 stocks we …

LLY mentioned

Sharemaestro market context Trend signal active 52 weeks +54.2%